![Jürg Eckhardt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jürg Eckhardt
Directeur/Membre du Conseil chez
TargeGen, Inc.
Profil
Jürg Eckhardt is currently a Director at TargeGen, Inc. He previously held Director positions at Calypso Medical Technologies, Inc., NeurogesX, Inc., and Anteis SA. He was also the Chairman of Lumavita AG.
Additionally, he worked as a Management Consultant at McKinsey & Co., Inc. and as an Investment Manager at Global Life Science Ventures AG.
He was a Partner at Bellevue Asset Management (Venture Capital) from 2004 to 2016.
Dr. Eckhardt holds an MBA from INSEAD and a doctorate from the University of Basel.
Postes actifs de Jürg Eckhardt
| Sociétés | Poste | Début |
|---|---|---|
TargeGen, Inc.
 TargeGen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures vascular biopharmaceutical products | Directeur/Membre du Conseil | - |
Anciens postes connus de Jürg Eckhardt
| Sociétés | Poste | Fin |
|---|---|---|
Bellevue Asset Management (Venture Capital)
 Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is an active manager which invests primarily in private companies developing and marketing drugs and medical devices or providing healthcare services. The investment focus is on the US and Europe. The firm typically invests USD 7-15 million over an investee companies' lifetime, seeking to invest in companies with entrepreneurial individuals/teams, the ability to attain milestones in a timely manner, an advanced clinical pipeline, a proven technology base, good commercialization potential, growing markets, a medical need, significant competitive advantages, barriers to entry and a clear path to liquidity. It generally co-invests in syndicates with other venture capital firms, both leading the syndicate and acting as an active co-investor. It normally seeks representation on the boards of their portfolio companies, partnering with management to create value. The firm typically holds an investment for three to five years. | Analyste en capital-investissement | 31/08/2016 |
Lumavita AG
 Lumavita AG Medical/Nursing ServicesHealth Services Develops and commercializes antiinfectives for women's health | Président | 07/01/2014 |
Global Life Science Ventures AG
 Global Life Science Ventures AG Investment ManagersFinance GLSV-Switzerland is an active, long-term manager which aims to create and build value exclusively in life science companies in the UK, Switzerland, German-speaking countries and the US which offer superior technologies and customer benefits. They invest in many areas of the life sciences including the cancer, immunology, vaccines, biopharmaceuticals, indication-specific genomics, genomics tools, diagnostics, medical devices, healthcare services and cardiovascular areas. The firm primarily invests in early-stage companies that operate in significant markets with considerable upside potential, as well as in later-stage companies, including buyouts, which meet their investment criteria. In their home markets, GLSV-Switzerland is the lead investor or an active co-investor, while outside of their home markets they only act as a knowledgeable co-investor. By investing in a syndicate, they offer investees access to the capital, experience and networks of international venture capitalists that invest in the life sciences on a global scale and who share the same investment criteria and philosophy. GLSV-Switzerland fosters openness, flexibility and dialogue on all issues relating to their investments and provides coaching, support, expertise and access to their network of scientific, industrial and financial professionals from prestigious institutions to their investee companies. The firm can invest up to 10% of their fund volume in an investee company. Depending on the stage of development of the company and the likelihood of further funding requirements, they generally invest €2-€5 million per company in each round of investment. | Private Equity Investor | 01/10/2004 |
swiss smile Holding AG
 swiss smile Holding AG Medical/Nursing ServicesHealth Services Operates as a holding company with interests in operates a chain of dental clinics | Corporate Officer/Principal | - |
| NEUROGESX, INC | Directeur/Membre du Conseil | - |
Formation de Jürg Eckhardt
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
7
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Calypso Medical Technologies, Inc.
 Calypso Medical Technologies, Inc. Medical/Nursing ServicesHealth Services Provides radiation therapy and medical services | Health Services |
TargeGen, Inc.
TargeGen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures vascular biopharmaceutical products | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
INSEAD
 INSEAD Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NeurogesX, Inc.
 NeurogesX, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel pain management therapies | Health Technology |
University of Basel
 University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Global Life Science Ventures AG
Global Life Science Ventures AG Investment ManagersFinance GLSV-Switzerland is an active, long-term manager which aims to create and build value exclusively in life science companies in the UK, Switzerland, German-speaking countries and the US which offer superior technologies and customer benefits. They invest in many areas of the life sciences including the cancer, immunology, vaccines, biopharmaceuticals, indication-specific genomics, genomics tools, diagnostics, medical devices, healthcare services and cardiovascular areas. The firm primarily invests in early-stage companies that operate in significant markets with considerable upside potential, as well as in later-stage companies, including buyouts, which meet their investment criteria. In their home markets, GLSV-Switzerland is the lead investor or an active co-investor, while outside of their home markets they only act as a knowledgeable co-investor. By investing in a syndicate, they offer investees access to the capital, experience and networks of international venture capitalists that invest in the life sciences on a global scale and who share the same investment criteria and philosophy. GLSV-Switzerland fosters openness, flexibility and dialogue on all issues relating to their investments and provides coaching, support, expertise and access to their network of scientific, industrial and financial professionals from prestigious institutions to their investee companies. The firm can invest up to 10% of their fund volume in an investee company. Depending on the stage of development of the company and the likelihood of further funding requirements, they generally invest €2-€5 million per company in each round of investment. | Finance |
Lumavita AG
Lumavita AG Medical/Nursing ServicesHealth Services Develops and commercializes antiinfectives for women's health | Health Services |
Anteis SA
 Anteis SA Medical/Nursing ServicesHealth Services Modifies and functionalizes injectable hyaluronic acid for a range of medical applications | Health Services |
swiss smile Holding AG
swiss smile Holding AG Medical/Nursing ServicesHealth Services Operates as a holding company with interests in operates a chain of dental clinics | Health Services |
Bellevue Asset Management (Venture Capital)
Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is an active manager which invests primarily in private companies developing and marketing drugs and medical devices or providing healthcare services. The investment focus is on the US and Europe. The firm typically invests USD 7-15 million over an investee companies' lifetime, seeking to invest in companies with entrepreneurial individuals/teams, the ability to attain milestones in a timely manner, an advanced clinical pipeline, a proven technology base, good commercialization potential, growing markets, a medical need, significant competitive advantages, barriers to entry and a clear path to liquidity. It generally co-invests in syndicates with other venture capital firms, both leading the syndicate and acting as an active co-investor. It normally seeks representation on the boards of their portfolio companies, partnering with management to create value. The firm typically holds an investment for three to five years. | Finance |
